CD274 and neoplasm: The 6.5-year OS rates were 48% with nivolumab plus ipilimumab, 35% with nivolumab, and 21% with ipilimumab in patients with PD-L1 < 1% tumours, and 51% with nivolumab plus ipilimumab, 50% with nivolumab, and 25% with ipilimumab in patients with PD-L1 > 1% tumours, respectively (13).